Idiopathic Myelofibrosis in an Infant.
Summary of "Idiopathic Myelofibrosis in an Infant."
Idiopathic Myelofibrosis (MF) is an extremely rare condition in children. It has a very variable clinical spectrum. Cases of secondary myelofibrosis associated with Vitamin D deficiency and Systemic Lupus Erythematosus have been reported from India .In this case report, the authors describe clinical signs, laboratory findings and histologic features in a 6 month old infant with Idiopathic myelofibrosis.
Affiliation
Department of Pathology, Lilavati Hospital and Research Centre, Bandra (W), Mumbai, India.
Journal Details
This article was published in the following journal.
Name: Indian journal of pediatrics
ISSN: 0973-7693
Pages:
Links
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/21188553
- DOI: http://dx.doi.org/10.1007/s12098-010-0340-6
Medical and Biotech [MESH] Definitions
Infant, Premature
A human infant born before 37 weeks of GESTATION.
Infant, Postmature
An infant born at or after 42 weeks of gestation.
Infant Behavior
Any observable response or action of a neonate or infant up through the age of 23 months.
Infant Welfare
Organized efforts by communities or organizations to improve the health and well-being of the infant.
Infant, Newborn
An infant during the first month after birth.
PubMed Articles
76-year old patient with suspected but not confirmed "idiopathic myelofibrosis"
A 76-year old patient was referred to our Oncology Unit due to hepatosplenomegaly, anemia, thrombocytopenia, eosinophilia, elevation of lactat dehydrogenase and leucocytosis with occurrence of myeloid...
A 56-year-old male with chronic idiopathic myelofibrosis and cytogenetic finding of 20q- after a period of 10 months developed acute Philadelphia-positive lymphoblastic leukemia. Immunophenotyping of...
In November 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-molecule inhibitor of Janus kinases, was approved by the US Food and Drug Administration for the treatment of patients with intermediat...
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Treatment options for myelofibrosis are limited. We evaluated the efficacy and safety of ruxolitinib, a potent and selective Janus kinase (JAK) 1 and 2 inhibitor, as compared with the best available t...
MYELOFIBROSIS IN CHILDREN: Experience at a Single Tertiary Care Center in India.
The authors describe 10 cases of myelofibrosis diagnosed and managed at their center over 16 years. There were 2 and 8 cases, respectively, of primary and secondary myelofibrosis. All patients present...
Clinical Trials
The purpose of this study is to determine the effects (good and bad) of Gleevec in patients with BCR-negative myeloproliferative disorders including myelofibrosis with myeloid metaplasia a...
A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis
The study consists of two phases: The first portion of the study is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when...
Sunitinib in Treating Patients With Idiopathic Myelofibrosis
RATIONALE: Sunitinib may stop the growth of abnormal cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the abnormal cells. PURPOSE: This phase II...
Male or female individuals, aged 18 years or older who have been diagnosed with Myelofibrosis (either Primary Myelofibrosis (PMF) or Post-Polycythemia Vera Myelofibrosis (PPV-MF) or Post-E...
Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder
To determine the prevalence of myelofibrosis in patients with primary pulmonary hypertension, and to discover if the fibrosis in these patients is primary (AMM) or secondary.
